Gabrail Cancer & Research Center
Skip to content
  • For Patients
    • New Patients
      • Request An Appointment
      • Referrals
    • What to expect?
      • Symptom Management
    • Patient Testimonials
    • Satisfaction Survey
  • Our Services
    • Clinical Trials
      • Clinical Research Trials (CRT)
    • Infusion Therapy
    • Instant Imaging
    • On Site Lab Services
    • The Liberty Pharmacy
    • Family Cancer Registry
    • Community Outreach
  • Clinical Trials
    • Clinical Trials at GCC
    • About Clinical Trials
      • Clinical Trial Phases
    • For Sponsors
      • Sponsor Testimonials
    • Approved Oncology Drugs
  • About Us
    • Physicians
    • Our Staff
    • Mission Statement
    • Location
    • Careers
  • Media
    • Podcasts
      • The Cancer Gene
      • Good Medicine Is Cheaper Medicine
    • Radio
    • TV
    • Articles
August 12, 2016 gabrailcancercenter

Breast Cancer

The Gabrail Cancer Center currently has many Clinical Trial opportunities. For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or email CSmith@GabrailCancerCenter.com.

An open-label randomized phase 2 trial of SAR439859, versus endocrine monotherapy as per physician’s choice in premenopausal and postmenopausal patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer with prior exposure to hormonal therapies

A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy

 

Return to Clinical Trials at GCC

Subscribe to Podcast

4875 Higbee Ave NW Canton, OH 44718
cantondesk@gabrailcancercenter.com
330-492-3345
  • Facebook link
  • Instagram link
Zerif Lite developed by ThemeIsle
This website uses cookies to improve your experience. We'll assume you accept this policy as long as you are using this websiteAcceptView Policy